January 17, 2023 11:44 AM EST
News Briefing

Aeter­na dis­con­tin­ues vac­cine de­vel­op­ment; Idera re­brands as Ac­er­a­gen

Paul Schloesser

Associate Editor

Kyle LaHucik

Senior Reporter

As biotechs start to de­tail 2023 plans — M&A, new em­phases in drug R&D and more with in­vestors — oth­ers are start­ing to trim back or us­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

GSK to pay $1.2B up­front to snag Boston Phar­ma’s mid-stage MASH hope

No­vo turns to Septer­na for oral obe­si­ty med­i­cines in deal worth up to $2.2B

TIG­IT grave­yard ex­pands as GSK drops late-stage as­set with iTeos

Bay­er starts 2025 by cut­ting 2,000 jobs as it homes in on year-end re­haul tar­get

Some gener­ics, biosim­i­lar drug­mak­ers say they can with­stand tar­iff im­pact

Ad­vo­ca­cy groups and ex­perts call for decade-long ban on germline edit­ing

A service from the Financial Times